West Pharmaceutical Services (WST)
(Delayed Data from NYSE)
$256.64 USD
-1.71 (-0.66%)
Updated Sep 17, 2025 04:00 PM ET
After-Market: $256.67 +0.03 (0.01%) 7:58 PM ET
1-Strong Buy of 5 1
D Value D Growth D Momentum D VGM
Fundamental Charts
About Cash from Investing (TTM)
The company's trailing twelve month (TTM) Cash from Investing is the sum of the company's past 12 months cash position resulting from any gains or losses from investments in the financial markets, operating activities, and changes resulting from amounts spent on investments in capital assets such as plant and equipment. When evaluating the Cash from Investing value, it is important to consider each of the various activities which contribute to the overall change in cash position. A company can have a negative cash flow from investing and have a positive cash from Cash from operations or financing.
WST 256.64 -1.71(-0.66%)
Will WST be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for WST based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for WST
BWAY Shares Gain on FDA Nod for Accelerated Deep TMS Depression Care
CAH Strengthens Distribution With New Consumer Health Logistics Hub
WST: What are Zacks experts saying now?
Zacks Private Portfolio Services
GEHC Expands Women's Health Portfolio With AI-Enabled Voluson
ISRG Stock Dips Despite Introducing Real-Time Insights on da Vinci 5
GEHC Eyes icometrix Buyout to Strengthen Neurology Imaging Portfolio
Other News for WST
WST rises 0.32% on September 16, leaving the technical picture intact
Optimistic Long-Term Growth Outlook for Wingstop Amid Strategic Initiatives and Expansion Plans
Is WST consolidating before a move? NR7 shows up after gaining 1.59%
Rothschild & Co Initiates Coverage on WST with a 'Buy' Rating | WST Stock News
West Pharmaceutical Services (WST) Has a New Rating from Redburn Atlantic